Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer

Acta Oncologica

Volumn 52, Issue 8, 2013, Pages 1691-1698

  Kersten, Christian ^a   Louhimo, Johanna ^b   Ålgars, Annika ^c   Lahdesmaki, Aleksi ^d   Cvancerova, Milada ^e   Stenstedt, Kristina ^f   Haglund, Caj ^b   Gunnarsson, Ulf ^g  

^a Southern Hospital Trust   (Norway)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d Porvoo Hospital   (Finland)

^e UNIVERSITY OF AGDER   (Norway)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ALBUMIN; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; COLON CANCER; DATA BASE; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS RESECTION; MORBIDITY; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; BODY MASS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; EMERGENCY SURGERY; INTESTINE OBSTRUCTION; LEUKOCYTE COUNT; LYMPH NODE METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885438343     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.835494     Document Type: Article

References (25)

1. Patama TEG, Klint Å, Larønningen S, Ólafsdó ttir GH, Pukkala E. Small-area based map animations of cancer mortality in the Nordic countries, 1971-2003. Cancer Union 2008. Available from: http://astracancerfi/cancermaps/Nordic/mort [cited 2013 June 15].
2. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J clin oncol 2011; 29: 610-8.
3. Roxburgh CS, McMillan DC. Role of systemic infl ammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-63.
4. Chung YC, Chang YF. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 2003; 15: 369-73.
5. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Tumour infl ammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009; 45: 2138-45.
6. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000; 7: 617-23.
7. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration. PLoS Med 2012; 9: e1001216.
8. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
9. Roxburgh CS, McMillan DC. The role of the in situ local infl ammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012; 38: 451-66.
10. Crozier JE, McMillan DC, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, et al. Tumor size is associated with the systemic infl ammatory response but not survival in patients with primary operable colorectal cancer. J Gastro-enterol Hepatol 2007; 22: 2288-91.
11. Wong JJ, Hawkins NJ, Ward RL, Hitchins MP. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Mod Pathol 2011; 24: 396-411.
12. Grivennikov SI, Greten FR, Karin M. Immunity, infl amma-tion, and cancer. Cell 2010; 140: 883-99.
13. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, et al. Use of aspirin post-diagnosis improves survival for colon cancer patients. Br J Cancer 2012; 106: 1564-70.
14. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K, et al. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 2008; 98: 540-4.
15. Sugimoto K, Komiyama H, Kojima Y, Goto M, Tomiki Y, Sakamoto K. Glasgow prognostic score as a prognostic factor in patients undergoing curative surgery for colorectal cancer. Dig Surg 2013; 29: 503-9.
16. Bystrom P, Berglund A, Nygren P, Wernroth L, Johansson B, Larsson A, et al. Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncol 2012; 51: 849-59.
17. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Infl ammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen. Ann Surg Oncol 2012; 19: 3422-31.
18. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of infl ammation-based prognostic scores in patients with cancer. A Glasgow Infl ammation Outcome Study. Eur J Cancer 2011; 47: 2633-41.
19. Roxburgh CS, Platt JJ, Leitch EF, Kinsella J, Horgan PG, McMillan DC. Relationship between preoperative comorbidity, systemic infl ammatory response, and survival in patients undergoing curative resection for colorectal cancer. Ann Surg Oncol 2011; 18: 997-1005.
20. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic infl ammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003; 89: 1028-30.
21. Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg 2010; 34: 2393-8.
22. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res 2011; 71: 5601-5.
23. Eggermont AM. Therapeutic vaccines in solid tumours: Can they be harmful? Eur J Cancer 2009; 45: 2087-90.
24. Marhall MA, Ribas A, Huang B. Evaluation of baseline serum C-reactive protein (CRP) and benefit from treme-limumab compared to chemotherapy in first-line melanoma. J Clin Oncol 2010; 28(Suppl 2609). (Meeting Abstracts).
25. Ali R, To h HC, Chia WK, Investigators AT. The utility of aspirin in Dukes C and high risk Dukes B colorectal cancer-the ASCOLT study: Study protocol for a randomized controlled trial. Trials 2011; 12: 261.